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Abstract
Background/Objectives: Chronic heart failure (CHF) is one of the most important public health concerns in the
industrialized world having increasing incidence and prevalence. Although there are several studies describing the
prevalence of heart failure with reduced ejection fraction (HFREF) and heart failure with normal ejection fraction (HFNEF) in
selected populations, there are few data regarding the prevalence and the determinants of symptomatic heart failure in the
general population.
Methods: Cross-sectional data of a population-based German sample (1,779 subjects aged 45–83 years) were analyzed to
determine the prevalence and determinants of chronic SHF and HFNEF defined according to the European Society of
Cardiology using symptoms, echocardiography and serum NT-proBNP. Prevalence was age-standardized to the German
population as of December 31st, 2005.
Results: The overall age-standardized prevalence of symptomatic CHF was 7.7% (95%CI 6.0–9.8) for men and 9.0% (95%CI
7.0–11.5) for women. The prevalence of CHF strongly increased with age from 3.0% among 45–54- year-old subjects to
22.0% among 75–83- year-old subjects. Symptomatic HFREF could be shown in 48% (n = 78), symptomatic HFNEF in 52%
(n = 85) of subjects with CHF. The age-standardized prevalence of HFREF was 3.8 % (95%CI 2.4–5.8) for women and 4.6 %
(95%CI 3.6–6.3) for men. The age-standardized prevalence of HFNEF for women and men was 5.1 % (95%CI 3.8–7.0) and 3.0 %
(95%CI 2.1–4.5), respectively. Persons with CHF were more likely to have hypertension (PR= 3.4; 95%CI 1.6–7.3) or to have had
a previous myocardial infarction (PR= 2.5, 95%CI 1.8–3.5).
Conclusion: The prevalence of symptomatic CHF appears high in this population compared with other studies. While more
women were affected by HFNEF than men, more male subjects suffered from HFREF. The high prevalence of symptomatic
CHF seems likely to be mainly due to the high prevalence of cardiovascular risk factors in this population.
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Introduction
Chronic heart failure (CHF) is one of the most important health
concerns in the industrialized world. Whereas survival with CHF
has improved over the last decades, its prevalence and incidence
are steadily increasing [1].
According to the European Society of Cardiology (ESC), heart failure
is defined as a syndrome that consists of symptoms or signs typical
of heart failure, such as shortness of breath or raised jugular
venous pressure, and objective evidence of a structural or
functional abnormality of the heart at rest, e.g., in an echocar-
diogram. [2]. Additionally, the diagnosis of heart failure is
supported by the laboratory analysis of natriuretic peptides such
as NT-proBNP or BNP which reflect neurohormonal activation.
The diagnostic value of these biomarkers is characterized by a
high negative predictive value for the exclusion of LV dysfunction.
Furthermore, the natriuretic peptide concentration in plasma/
serum (particularly B-type natriuretic peptide, BNP) correlates
with left ventricular (LV) function and mass [3,4].
The objective evidence of normal systolic LV function
accompanied by an impaired diastolic function in about one third
of patients with clinical signs of heart failure led to the
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differentiation between heart failure with reduced ejection fraction
(HFREF) and heart failure with normal ejection fraction (HFNEF)
[5,6].
Systolic dysfunction is primarily considered as reduced contrac-
tion ability of the heart muscle resulting in a decreased ejection
fraction. In contrast, diastolic dysfunction is characterized by a
disturbed relaxation and dilatation of the left ventricle after the
contraction. The filling of the ventricles is slow or incomplete
unless atrial blood pressure rises, but the ejection fraction is
preserved. Although cardiac structure and function differ substan-
tially in systolic and diastolic dysfunction, the clinical signs and
symptoms are nearly the same [7]. However, clinical character-
istics such as sex, hypertension, chronic obstructive pulmonary
disease (COPD) or atrial fibrillation differ between patients with
decompensated HFNEF and HFREF [8].
Despite a wide variation in the reported prevalence of chronic
heart failure, published data suggest that the prevalence has been
steadily increasing over the past decades [9]. Overall, the
prevalence of heart failure is estimated to be 1–2% in the
industrialized world and the incidence is estimated to be 5–10 per
1,000 persons per year [10]. Heart failure is hardly found in
subjects younger than 50 years, but in subjects above 50 years the
prevalence increases progressively with age. According to analyses
from the Rotterdam Study, the prevalence of symptomatic heart
failure increases from 0.5% among subjects aged 55–64 years to
almost 14% among subjects aged 85–94 years [11]. A population-
based study from the USA shows an increase of CHF prevalence
from 0.7% in the lowest age group (45–54 years) to more than 8%
in subjects aged over 74 years [12].
Many attempts have been made to describe the burden of CHF
in the population. Although there are several studies estimating the
prevalence of HFREF and HFNEF in selected populations [10–
16] there are few data regarding the prevalence and the
determinants of symptomatic HFREF as well as HFNEF in the
general population. Moreover, there is a lack of data on the
distribution of symptomatic CHF among the general population
using natriuretic peptides as diagnostic markers. The main
objective of this study was therefore to describe the burden of
symptomatic CHF and the distribution of HFREF vs. HFNEF
using a diagnostic approach including self-reported symptoms,
echocardiographic information on systolic and diastolic function,
and NT-proBNP level in an elderly general population with an
especially high burden of adverse risk factors, such as hyperten-
sion, obesity and diabetes [17,18]. Furthermore, we aimed to
describe the association of hypertension, previous MI, coronary
heart disease and obesity with CHF, HFREF and HFNEF.
Methods
To determine the prevalence of overall CHF we used cross-
sectional data from the baseline examination of the CArdiovascular
Risk Factors, Living and Ageing in Halle Study (CARLA Study),
conducted between December 2002 and January 2006 in Halle
(Saale) in Saxony-Anhalt. The CARLA Study is a German
population-based prospective cohort study. Details of the study
design and methods have been described elsewhere [19,20]. The
study population comprises 812 female and 967 male inhabitants
of the city of Halle aged 45 to 83 years and the baseline response
was 64%. Subjects were excluded if they were too ill to participate
in the 4-hour examination. Furthermore, we did not include
subjects living in nursing homes. An analysis of 373 non-
respondents was carried out in order to obtain information on
prevalent disease, selected behavioural factors and sociodemo-
graphic variables.
The study was approved by the Ethics Committee of the Medical
Faculty of theMartin-Luther-University Halle-Wittenberg and by the
State Data Privacy Commissioner of Saxony-Anhalt and conforms
with the principles outlined in the Declaration of Helsinki [21]. All
participants gave written informed consent. Data were collected with
standardized, computer-assisted personal interviews and medical
examinations by trained study nurses. To examine left ventricular
(LV) function two-dimensional Doppler-echocardiography was
performed in all subjects participating in the study by a physician
who had been specifically trained and certified for this study. Serum
levels of NT-proBNP were determined in all subjects from non-
fasting venous blood samples after a 30 minute rest, using the Elecsys
proBNP sandwich immunoassay (Roche Diagnostics).
Definition of heart failure in the study population
The diagnosis of CHF was based on (a) self-reported symptoms
suggestive of heart failure in combination with (b) an increase of
the NT-proBNP serum concentration above 220 pg/ml and (c) on
the evidence of systolic or diastolic dysfunction using echocardio-
graphic parameters according to the recommendation of the ESC
[22] (see Fig. 1). Information on symptoms of heart failure was
obtained via standardized interview. Individuals were asked
whether they suffer from dyspnoea, fatigue, or oedema. Further-
more, the severity of these symptoms was assessed in order to
determine the NYHA classification.
The echocardiographic parameters LV ejection fraction (LVEF)
and LV diameter index (LVDI) were used to determine the left
ventricular systolic function. According to the recommendation of
the ESC, systolic function was considered as normal or mildly
reduced if LVEF was greater than 0.5 and LVDI was less than
3.8 cm/m2 in male subjects and less than 3.7 cm/m2 in female
subjects [22,23]. The LVEF was determined from the long
parasternal axis and calculated according to the Teichholz
equation. Diastolic function was determined based on the
following parameters: ratio of peak early (E) to peak atrial (A)
Doppler mitral valve flow velocity (E/A), deceleration time (DT),
left atrial diameter index (LADI) and the sex-specific left
ventricular mass index (LVMI). To calculate the LVMI we used
the ASE-cube formula according to international guidelines
[23,24]. The cut-off values for these parameters are shown in
Figure 1. For NT-proBNP we used a cut-off value of 220 pg/ml.
All subjects with self-reported symptoms and a reduced LV
systolic function (LVEF #50% or LVDI $3.8 cm/m2 for males
and $3.7 for females) were classified as having heart failure
with reduced ejection fraction (HFREF). Those subjects with
self-reported symptoms suggestive of heart failure, an elevated NT-
proBNP (.220 pg/ml), and a reduced diastolic function (accord-
ing to the above mentioned echocardiographic criteria) but a
normal or only mildly reduced LV systolic function (LVEF .50%
and LVDi ,3.8 cm/m2 for males and ,3.7 for females) were
classified as having heart failure with normal ejection
fraction (HFNEF) (see Figure 1).
Definition of covariates
Hypertension was defined as mean systolic blood pressure (SBP)
$140 mmHg, and/or mean diastolic BP $90 mmHg, and/or use
of antihypertensive medication according to the anatomic
therapeutic chemical classification system (ATC codes C02, C03,
C07, C08, C09). Blood pressure measurement was performed in
sitting position after a 5-minute resting phase using the OMRON
HEM-705CP device. The average of the second and third of three
measurements was used for further analyses. Prevalent myocardial
infarction (MI) was defined as self-reported physician-diagnosed
MI and/or definite MI by Minnesota code of the 10-second ECG
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[25]. ECGs were processed by the Modular ECG Analysis System
(MEANS) [26] to obtain Minnesota codes. If the subject did not
report a MI, but the Minnesota code indicated a definite MI, the
ECG-based diagnosis was verified by a cardiologist. Coronary
heart disease (CHD) was defined as definite MI, and/or self-
reported coronary artery bypass graft, and/or self-reported
percutaneous coronary intervention. Cardiovascular disease was
defined as CHD, and/or self-reported physician-diagnosed stroke,
and/or carotid surgery. Diabetes mellitus (DM) was defined as self-
reported physician-diagnosed diabetes and/or use of antidiabetic
medication (ATC code A10).
Statistical analysis
All statistical analyses were performed using the Statistical
Analysis Software (SAS 9.2, SAS Institute, Cary, NC, USA).
Prevalences were directly age-standardized to the German
standard population as of December 31st, 2005. The correspond-
ing confidence intervals were calculated according to the
recommendations of Fay and Feuer [27]. Overall means of risk
factors were calculated using age-specific weights of the standard
population. To describe the association between CHF and
different determinants we used the prevalence ratio (PR) as effect
measure. Therefore, we calculated generalized linear models with
the SASH procedure PROC GENMOD using the binomial
distribution and the log link [28].
Results
Study population
The study population of the CARLA Study comprises 812
women and 967 men aged 45–83 years at baseline with a mean
age (SD) of 63.8 (9.9) and 64.9 (10.2) years, respectively. The
baseline characteristics of this population are shown in Table 1.
Almost 75% of the study population showed hypertension. The
prevalence of cardiovascular diseases was considerably higher in
men than in women, while diabetes showed a similarly high
prevalence in both sexes. Although the mean body mass index
(BMI) was quite similar in both sexes, women were more likely to
be obese than men (34% and 29%, respectively, with a BMI of
30 kg/m2 or more).
Prevalence of chronic heart failure
Symptomatic CHF was diagnosed in 163 subjects (86 men and
77 women) resulting in an age-standardized prevalence of 8.3%
(95%CI 7.0–9.8) in the total study group and 7.7% (95%CI 6.1–
9.8) in men and 9.0% (95%CI 7.0–11.5) in women, respectively.
The overall age-standardized prevalence of symptomatic HFREF
and symptomatic HFNEF was 4.2% (95%CI 3.3–5.5) and 4.0%
(95%CI 3.2–5.1), respectively. Overall, the prevalence of CHF did
not differ between men and women. However, whereas more men
were affected by symptomatic HFREF (age-adjusted prevalence
ratio (PR) for male vs. female subjects 1.5 (95%CI 0.9–2.4)), more
women were affected by symptomatic HFNEF, (age-adjusted PR
for female vs. male subjects 1.8 (95%CI 1.2–2.7) (see Figure 2). Of
all subjects with left ventricular dysfunction (either systolic or
Figure 1. Algorithm to define symptomatic CHF.
doi:10.1371/journal.pone.0059225.g001
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diastolic) 31% did not report symptoms suggestive of heart failure.
Asymptomatic CHF was more common in men (36%) than in
women (23%).
The prevalence of symptomatic CHF strongly increased with
age from 3.0% among 45–54- year-old subjects to 22.0% among
75–83- year-old subjects. Figure 3 shows the age-specific
prevalence of overall symptomatic CHF, SHF and HFNEF for
5-year age groups in men and women. The prevalence of heart
failure increased from 1.4% for men aged 45–54 years to 22.6%
for men aged $75 years. For women, the prevalence rose from
5.7% in the lowest to 30.0% in the highest age group.
While men showed a lower LVEF than women (0.62% (SD
0.09) vs. 0.65% (SD 0.08)) women showed a higher NT-proBNP
serum concentration (median 65.5 pg/ml (IQR 33.5–140.7) vs.
92.5 pg/ml (IQR 51.7–158.3)). Subjects with HFNEF showed the
highest LVMI (mean 184.0 g/m2 (SD 51.9)). Subjects with
HFNEF showed the highest NT-proBNP serum concentration
(median 424.5 pg/ml (IQR 279.5–808.4)) followed by subjects
with HFREF (259.3 pg/ml (IQR 86.2–846.1)). As Table 2 shows,
about half of all subjects with SHF and HFNEF were in NYHA
class II and about one third were in NYHA class III. More than
10% of all subjects with SHF could be classified as NYHA class IV
and almost 18% of all subjects with HFNEF as NYHA class IV.
Figure 4 shows the prevalence of the aforementioned four
criteria used to define CHF among the study population
(regardless of a CHF diagnosis). About two thirds (67%, 95%CI
60.8–72.9) of all women reported signs and symptoms suggestive
of heart failure, such as breathlessness or fatigue, while less than
half of all men (44%; 95%CI 39.9–49.0) reported such complaints.
About 15% of all men or women showed a NT-proBNP serum
concentration above 220 pg/ml. A reduced systolic function was
found in 8% (95%CI 6.3–9.9) among men and in 5% (95%CI 3.1–
6.4) among women. About one fourth of all women (23%, 95%CI
20.5–27.5) and almost one sixth of all men (15.5%, 95%CI 13.1–
18.3) showed echocardiographic signs of an impaired diastolic
function.
Determinants
Among the prevalent cardiovascular diseases and risk factors
that were analyzed as determinants of CHF, hypertension was the
strongest determinant of CHF. The age- and sex-adjusted
prevalence ratio (PR) for subjects with hypertension vs. subjects
without hypertension was 3.4 (95%CI 1.6–7.3). For subjects with
CHD versus subjects without CHD the age- and sex-adjusted PR
was 2.3 (95%CI 1.6–3.1). Figure 5 shows the PRs for hypertension,
CHD and myocardial infarction (MI) for all subjects with CHF as
well as for those with SHF and HFNEF. While CHD or
Table 1. Baseline characteristics of the CARLA Study population (2002–2006).
Women (N=812) Men (N=967)
N
Proportion1/
Mean/Median
(95% Confidence
Interval/IQR) N
Proportion1/
Mean/Median
(95% Confidence
Interval/IQR)
Age (yrs) 812 63.8 (63.1–64.4) 967 64.9 (64.2–65.5)
SBP2 (mmHg) 812 140.4 (138.9–142.0) 966 145.4 (144.2–146.7)
DBP2 (mmHg) 812 83.5 (82.8–84.3) 966 86.9 (86.2–87.5)
Glucose (mmol/l) 807 5.78 (5.67–5.89) 960 6.13 (6.01–6.25)
Body mass index (kg/m2) 812 28.5 (28.1–28.9) 967 28.2 (27.9–28.4)
Waist-to-hip ratio (WHR) 812 0.88 (0.88–0.89) 967 1.0 (1.0–1.01)
Smoking2:
Current 119 17.1 (14.0–20.8) 225 27.6 (23.8–31.9)
Past 140 18.1 (15.1–21.7) 496 46.9 (42.6–51.6)
Never 553 64.8 (59.3–70.8) 245 25.5 (22.2–29.3)
LV ejection fraction 777 0.65 (0.65–0.66) 902 0.62 (0.61–0.63)
LV mass (g/m2) 784 106.7 (104.7–108.6) 910 124.3 (119.5–129.2)
NT-proBNP (pg/ml)3 790 92.5 (51.7–158.3) 932 62.5 (33.5–140.7)
GFRMDRD
4 800 88.6 (87.2–90.1) 967 96.0 (94.5–97.4)
Disease prevalence:
Myocardial infarction 17 2.00 (1.00–3.00) 88 7.55 (5.91–9.20)
Stroke 27 2.99 (1.85–4.14) 42 3.57 (2.46–4.68)
Cardiovascular Disease (CVD)5 48 5.52 (3.92–7.13) 153 12.84 (10.7–14.9)
Hypertension6 608 72.0 (66.0–78.0) 789 78.8 (72.9–84.6)
Diabetes mellitus7 120 13.3 (10.9–15.7) 154 14.2 (11.9–16.6)
1Proportions age-standardized to the age-distribution of the German standard population as of 31.12.2005, means weighted with age-specific weights of standard
population (except for mean age)
2SBP = systolic blood pressure, DBP = diastolic blood pressure, smoking = smoking tobacco products defined as cigarettes/cigars/pipes,
3given as median and inter-quartile-range
4glomerular filtration rate according to the simplified MDRD (Modification of Diet in Renal Disease) equation
5CVD: including prevalent myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, stroke, carotid surgery
6Hypertension defined as SBP . =140and/or DBP.= 90 mmHg, and/or use of antihypertensive medication by ATC code
7Diabetes defined as self-reported physician-diagnosed diabetes mellitus and/or use of anti-diabetic medication by ATC code
doi:10.1371/journal.pone.0059225.t001
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myocardial infarction as well as hypertension were strong
determinants for HFREF, for HFNEF, the single strongest
determinant was hypertension. While we could observe an
association between diabetes and HFNEF for men with an age-
adjusted PR of 2.0 (95%CI 1.1–4.0), for women we found an
association only between diabetes and HFREF (PR 2.5, 95%CI
1.1–5.4). Body mass index (BMI) was associated with overall CHF
for both sexes (PR 1.08 (95%CI 1.05–1.11)).
Discussion
The CARLA Study was initiated to investigate the prevalence
and incidence of cardiovascular diseases and their determinants in
an elderly general population. One of the main goals of this
investigation was to describe the burden of CHF, as it is one of the
most important public health concerns.
As the data suggest, the study population can be described as a
high-risk population with a high prevalence of cardiovascular risk
factors such as hypertension, obesity, low physical activity, or high
proportion of smokers. This is in accordance with other
investigations comparing the prevalence of cardiovascular risk
factors among different regions in Germany [29,30]. The reasons
for this high-risk profile compared with other German regions still
remain unclear. One possible explanation might be the relatively
poor socio-economic situation of the city of Halle, resulting in a
high unemployment rate (almost 18% in 2006), which is
considered a determinant of cardiovascular risk factors [31,32].
Figure 2. Age-standardized prevalence of symptomatic CHF,
HFREF and HFNEF (different denominators are due to by
differences in the number of subjects with missing data for
HFREF and HFNEF).
doi:10.1371/journal.pone.0059225.g002
Figure 3. Age-specific prevalence of symptomatic CHF, HFREF and HFNEF by 5-year-age-groups.
doi:10.1371/journal.pone.0059225.g003
Table 2. NYHA-Classification among subjects with
symptomatic SHF and HFNEF.
HFREF HFNEF
N Proportion (95%CI) N Proportion (95%CI)
NYHA II 42 53.8 (38.8–68.9) 43 50.6 (40.0–61.2)
NYHA III 28 35.9 (24.7–47.1) 27 31.8 819.5–44.1)
NYHA IV 8 10.3 (0.2–20.3) 15 17.6 (2.1–33.2)
doi:10.1371/journal.pone.0059225.t002
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In turn, the high proportion of cardiovascular risk factors could
explain the high prevalence of heart failure in this elderly
population.
The results of the CARLA Study showed a high prevalence of
symptomatic heart failure compared to other studies, for the
examined population aged 45 years and over [9]. For example, in
contrast to the data of the Rotterdam Study [11] or the Olmsted
County Study [12], the age-specific prevalence is noticeably higher
in this East-German population (see Table 3). On the other hand,
comparing the prevalence of systolic dysfunction (in this case
defined as an EF less than 40%) between the CARLA Study and
the Olmsted County Study the prevalence was quite comparable
except for the highest age group. This adds further evidence that
subjects with a high NYHA class of heart failure (especially
women) are underrepresented in our study. However, among these
studies different diagnostic approaches were used. While in the
Olmsted County Study medical records were reviewed for the
definition of heart failure in order to identify CHF diagnosis
according to the Framingham Criteria [12], in the Rotterdam
Study subjects were clinically examined in order to identify
symptoms suggestive of CHF (e.g. shortness of breath, ankle
oedema and pulmonary crepitations) [11]. As in the CARLA
Study, both studies performed echocardiography. One possible
explanation for the high prevalence of CHF (especially of HFNEF)
is the use of NT-proBNP as diagnostic criterion in our study. Due
to the diagnostic value of BNP as well as NT-proBNP we believe
that we were able to identify a certain proportion of unrecognized
HFNEF especially in subjects with symptoms suggestive of
pulmonary diseases. This may lead to a truely higher prevalence
compared with other population-based studies because they did
not use NT-proBNP to define heart failure. Since the current ESC
guideline on heart failure [33] recommend a NT-proBNP cutoff of
125 pg/ml, our diagnostic approach might be considered conser-
vative and, therefore, an overestimation of the heart failure
prevalence is unlikely. However, further studies are needed to
compare our findings with other populations.‘‘
Figure 4. Age-standardized prevalence of self-reported symp-
toms of CHF, NT-proBNP .220 pg/ml, systolic dysfunction and
diastolic impairment as measured by echocardiography (re-
gardless of any CHF diagnosis) (different denominators are
due to by differences in the number of subjects with missing
data for HFREF and HFNEF).
doi:10.1371/journal.pone.0059225.g004
Figure 5. Prevalence ratio for the association of symptomatic HF (total, HFREF and HFNEF) with hypertension, CHD and myocardial
infarction (adjusted for age and sex).
doi:10.1371/journal.pone.0059225.g005
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In the present study, women, especially in the higher age-
groups, were more likely to suffer from heart failure than men.
This fact is also in accordance with the data from above
mentioned studies [11,12]. Sex differences regarding CHF are
mainly due to a higher proportion of HFNEF among women. This
observation may be related to the different aetiology of CHF
between both sexes. Women are more likely to have hypertension
as the aetiology of CHF, whereas for men coronary heart disease
(including myocardial infarction) constitutes an important risk
factor for CHF. Therefore, the prognosis for women with CHF is
considered to be better than for men, since survival is worse for
subjects with ischemic cardiomyopathy [34].
We found a strong correlation of CHF with age with a
noticeable increase in CHF prevalence after the age of 70. The
age-specific increase of CHF was similar in subjects with HFNEF
compared to those with SHF. However, we observed a stronger
age-specific increase of HFNEF as well as SHF in women
compared with men.
Self-reported symptoms suggestive of CHF (dyspnoea, fatigue
and oedema) were very common in the examined population, with
an age-standardized prevalence of 44% in men and almost 67% in
women. These symptoms were only self-reported during the
standardized interview, and not verified by a clinical examination.
This raises the question, whether the high prevalence of self-
reported symptoms might have contributed to the high prevalence
of chronic heart failure in the studied population. According our
data, the relation between symptomatic heart failure and
asymptomatic (preclinical) heart failure is very comparable to that
in previous studies [12,35,36]. Therefore, we do not to believe,
that the high prevalence of heart failure symptoms has artificially
increased the CHF prevalence. However, several of these
symptoms, especially dyspnoea, can also be found in pulmonary
disease (mainly chronic obstructive pulmonary disease (COPD),
obesity, and depression [37]. Therefore, a meaningful proportion
of such symptoms cannot be attributed to cardiac failure. In our
sample, 85% of all subjects with self-reported physician-diagnosed
COPD reported symptoms which are typically also found in heart
failure, and almost two thirds of all subjects with a BMI of 30 kg/m2
or more reported such complaints. While the age-standardized
prevalence of COPD was quite similar between the sexes, we could
observe a higher prevalence of obesity among women. This might
be one possible explanation for the noticeably higher prevalence of
symptoms suggestive of CHF among women.
The differentiation between COPD and CHF is complicated by
the overlap of signs and symptoms. Furthermore, the accuracy of
the echocardiography can be decreased due to hyperinflated lungs.
However, the diagnosis HFNEF should be considered in subjects
with COPD when abnormal LV mass or left atrial enlargement
exist [38]. Evidence exist that there is a noticeable proportion of
subjects with unrecognized CHF among subjects with COPD,
which is estimated to be about 20% [39]. In our study population,
the prevalence of HFREF and HFNEF was 10% and 8%,
respectively, among all subjects with self-reported COPD. The
prevalence of HFREF and HFNEF among all subjects taking
antiobstructive medication (ATC R03) was 12% and 8%,
respectively. These findings may lead to the assumption that a
noticeable proportion of subjects with CHF and concomitant
COPD exist.Nevertheless, we used elevated levels of NT-proBNP
as another objective prerequisite for the diagnosis of heart failure.
Therefore, cardiac dysfunction is the most likely explanation for
heart failure symptoms even in subjects with, e.g., COPD or
obesity as comorbidities. Interestingly, the mean NT-proBNP level
in the subjects with HFNEF in the CARLA Study (779.7 pg/ml
(SD 949.7)) was far higher than the baseline level in the I-
PRESERVE trial, that tested the treatment of the AT-1 receptor
antagonist irbesartan in HFNEF [40] with 354 pg/ml and where
the majority of patients were in NYHA III functional class. This
provides further supporting evidence that the algorithm we used in
the CARLA-study actually identified subjects with heart failure as
the main reason for their symptoms.
Determinants
The aetiology of heart failure, especially of SHF, is fairly well
understood. However, there is a lack of information on the
aetiology of HFNEF and there is a need to understand the
underlying pathophysiology of HFNEF, in order to provide
effective treatment and improve outcomes for subjects with
HFNEF. Up to now, there is no pharmacologic therapy which
has shown to be effective in improving outcomes in patients with
HFNEF. Trials like the I-PRESERVE-trial did not show any
benefit to the patients [41]. Other studies showed only a weak
benefit of pharmacologic therapy for patients with HFNEF in
improving outcomes [42]. However, hypertension can be consid-
ered as the leading cause for the development of HFNEF [43–45].
Our analysis supports this hypothesis, showing a strong association
between HFNEF and hypertension among both sexes. The results
of our investigation underline that an appropriate treatment of
hypertension may be crucial for prevention of HFNEF. However,
there is a lack of evidence that a decline in HFNEF prevalence will
go along with a decline in hypertension prevalence. Hence,
prospective data are needed to describe the progression from
preclinical diastolic impairment to the onset of symptomatic CHF
in subjects with hypertension. Therefore, it is important to assess
what proportion of subjects in our study population with
preclinical diastolic dysfunction have progressed to HFNEF during
the 4-year follow-up of the CARLA-Study that has recently been
completed [19]. Besides hypertension as a main determinant,
myocardial infarction and coronary heart disease were strongly
associated with SHF but not with HFNEF. These findings are
consistent with the already known pathophysiology of heart failure
Table 3. Prevalence of Heart Failure in the CARLA Study compared with other population-based studies.
CARLA Study Rotterdam Study[11] Olmsted County Study[12]
(Germany) (The Netherlands) (USA)
45–54 years 3.0 0.7%
55–64 years 6.0 0.7% 1.3%
65–74 years 10.4 2.7% 1.5%
75–84 years 22.0 13% 8.4%
doi:10.1371/journal.pone.0059225.t003
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[41,46]. Furthermore, our data suggest that the determinants of
CHF in this population seem to be related to factors constituting
metabolic syndrome such as diabetes or obesity.
Strengths and limitations
The results of this study may be considered representative for
the general population aged 45 to 85 years since a random sample
from the population registry of the city of Halle had been selected,
and a high participation rate could be achieved. However, lower
participation rates among subjects too ill to attend the 4-hour
examination resulted in a moderate selection bias towards a
healthier population. Unfortunately, we do not have any
information on chronic heart failure from subjects who refused
to participate in the study. However, non-respondents reported a
higher prevalence of cardiovascular diseases and adverse risk
factors than study participants [20] which may have led to an
underestimate of the true prevalence and risk of heart failure in the
underlying population.
The main strengths of our study are the representative sample
and the highly standardized assessment of the data (e.g. blood
pressure measurement, ECG-recording, echocardiography) in
agreement with other German and international studies. For the
definition of heart failure, we were able to include information on
symptoms, biomarker NT-proBNP, and echocardiographic pa-
rameters. The use of natriuretic peptides is recommended in
addition to clinical information to detect diastolic dysfunction
especially in high-risk populations [47]. One limitation was,
however, that the symptoms suggestive of heart failure as well as
different disease prevalences (e.g. CHD, COPD, diabetes) were
self-reported and therefore we are not able to validate this
information. However, the diagnosis of prevalent myocardial
infarction was not only based on self-reported history of MI, but
also on Minnesota-coded ECG that was validated by cardiologists.
Regarding the study population, we cannot rule out the possibility
of a selection bias. Furthermore, due to the cross-sectional nature
of the data, caution must be exercised in the interpretation of the
results, especially concerning the association with potential
determinants.
Conclusion
In summary, we found a higher prevalence of overall HF in this
elderly population compared with previous population-based
studies, which is primarily due to the higher prevalence of
HFNEF, since the prevalence of systolic dysfunction is within the
range of these population-based studies except for the highest age-
groups. Our results underline the need for further elucidation of
determinants of diastolic dysfunction and its progression to
HFNEF in order to develop the prevention strategies that are
needed to address the heart failure epidemic in the ageing
population. Therefore, it will be important to assess what
proportion of subjects with preclinical diastolic dysfunction have
developed diastolic heart failure during the 4-year follow-up of the
CARLA Study that has recently been completed [19].
To our knowledge, this is the first investigation in Germany
describing the prevalence of symptomatic CHF among the general
population and, in addition, the first study in Europe to describe
the prevalence of symptomatic HFNEF.
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